(Q39598526)

13 September 2017

title

Cytomegalovirus viraemia has poor predictive value for the development of cytomegalovirus disease in patients with advanced HIV-infection (English)

1 reference

13 September 2017

0 references

Wiselka MJ

1

1 reference

13 September 2017

Nicholson KG

series ordinal

2

1 reference

13 September 2017

Rowley S

series ordinal

3

1 reference

13 September 2017

Bibby K

series ordinal

4

1 reference

13 September 2017

publication date

1 November 1999

1 reference

13 September 2017

1 reference

13 September 2017

volume

39

1 reference

13 September 2017

issue

3

1 reference

13 September 2017

page(s)

187-192

1 reference

Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Ocular manifestations of acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Cytomegalovirus retinitis and acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Survival of patients with the acquired immune deficiency syndrome after development of cytomegalovirus retinopathy. UCLA CMV Retinopathy Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

The diagnosis of cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Antiviral activity and mechanism of action of ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Prevalence of Resistance in Patients Receiving Ganciclovir for Serious Cytomegalovirus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

The pp65 antigenaemia test as a predictor of cytomegalovirus-induced end-organ disease in patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Detection of cytomegalovirus DNA in serum correlates with clinical cytomegalovirus retinitis in AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2899%2990047-6

7 January 2021

10.1016/S0163-4453(99)90047-6

Identifiers

DOI

1 reference

13 September 2017

1 reference